Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

381 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Gan HK, Reardon DA, Lassman AB, Merrell R, van den Bent M, Butowski N, Lwin Z, Wheeler H, Fichtel L, Scott AM, Gomez EJ, Fischer J, Mandich H, Xiong H, Lee HJ, Munasinghe WP, Roberts-Rapp LA, Ansell PJ, Holen KD, Kumthekar P. Gan HK, et al. Among authors: reardon da. Neuro Oncol. 2018 May 18;20(6):838-847. doi: 10.1093/neuonc/nox202. Neuro Oncol. 2018. PMID: 29077941 Free PMC article. Clinical Trial.
Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.
Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE 2nd, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, Reardon DA, Rich J, Stenzel T, Tourt-Uhlig S, Wikstrand C, Wong T, Williams R, Yuan F, Zalutsky MR, Pastan I. Sampson JH, et al. Among authors: reardon da. J Neurooncol. 2003 Oct;65(1):27-35. doi: 10.1023/a:1026290315809. J Neurooncol. 2003. PMID: 14649883 Clinical Trial.
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
Reardon DA, Quinn JA, Rich JN, Gururangan S, Vredenburgh J, Sampson JH, Provenzale JM, Walker A, Badruddoja M, Tourt-Uhlig S, Herndon JE 2nd, Dowell JM, Affronti ML, Jackson S, Allen D, Ziegler K, Silverman S, Bohlin C, Friedman AH, Bigner DD, Friedman HS. Reardon DA, et al. Neuro Oncol. 2004 Apr;6(2):134-44. doi: 10.1215/s1152851703000413. Neuro Oncol. 2004. PMID: 15134628 Free PMC article. Clinical Trial.
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Vredenburgh J, Gururangan S, Provenzale JM, Walker A, Schweitzer H, Bigner DD, Tourt-Uhlig S, Herndon JE 2nd, Affronti ML, Jackson S, Allen D, Ziegler K, Bohlin C, Lentz C, Friedman HS. Quinn JA, et al. Among authors: reardon da. Neuro Oncol. 2004 Apr;6(2):145-53. doi: 10.1215/S1152851703000498. Neuro Oncol. 2004. PMID: 15134629 Free PMC article. Clinical Trial.
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE 2nd, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS. Reardon DA, et al. J Clin Oncol. 2005 Dec 20;23(36):9359-68. doi: 10.1200/JCO.2005.03.2185. J Clin Oncol. 2005. PMID: 16361636 Clinical Trial.
Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.
Badruddoja MA, Penne K, Desjardins A, Reardon DA, Rich JN, Quinn JA, Sathornsumetee S, Friedman AH, Bigner DD, Herndon JE 2nd, Cahill A, Friedman HS, Vredenburgh JJ. Badruddoja MA, et al. Among authors: reardon da. Neuro Oncol. 2007 Jan;9(1):70-4. doi: 10.1215/15228517-2006-022. Epub 2006 Nov 15. Neuro Oncol. 2007. PMID: 17108065 Free PMC article. Clinical Trial.
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA. Desjardins A, et al. Among authors: reardon da. J Neurooncol. 2007 May;83(1):53-60. doi: 10.1007/s11060-006-9302-2. Epub 2007 Jan 24. J Neurooncol. 2007. PMID: 17245623 Clinical Trial.
Temozolomide in children with progressive low-grade glioma.
Gururangan S, Fisher MJ, Allen JC, Herndon JE 2nd, Quinn JA, Reardon DA, Vredenburgh JJ, Desjardins A, Phillips PC, Watral MA, Krauser JM, Friedman AH, Friedman HS. Gururangan S, et al. Among authors: reardon da. Neuro Oncol. 2007 Apr;9(2):161-8. doi: 10.1215/15228517-2006-030. Epub 2007 Mar 8. Neuro Oncol. 2007. PMID: 17347491 Free PMC article. Clinical Trial.
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE 2nd, McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, Dowell JM, Wong TZ, Zhao XG, Friedman HS, Bigner DD. Reardon DA, et al. Neuro Oncol. 2008 Apr;10(2):182-9. doi: 10.1215/15228517-2007-053. Epub 2008 Feb 20. Neuro Oncol. 2008. PMID: 18287339 Free PMC article.
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Reardon DA, Desjardins A, Vredenburgh JJ, Sathornsumetee S, Rich JN, Quinn JA, Lagattuta TF, Egorin MJ, Gururangan S, McLendon R, Herndon JE 2nd, Friedman AH, Salvado AJ, Friedman HS. Reardon DA, et al. Neuro Oncol. 2008 Jun;10(3):330-40. doi: 10.1215/15228517-2008-003. Epub 2008 Mar 21. Neuro Oncol. 2008. PMID: 18359865 Free PMC article. Clinical Trial.
381 results